muc1 peptide
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2001 (NCT01731587)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1Immunity, active
MUC1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- muc1 peptide
- muc1 peptide-poly-iclc adjuvant vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03300817 | Phase 1 | Dec 27, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00986609 | Early Phase 1 (Phase 1) | Aug 1, 2009 | Case Western Reserve University |
| NCT01731587 | Phase 1 | Jan 1, 2001 | Merck KGaA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Merck KGaA | For profit | 1 | 1 | 1 | 2001 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1